Recital 4, Regulation (EU) 2024/1052

In forcesince 10 Apr 2024

On 16 May 2018, the applicant also made a request to the Commission for the protection of proprietary data for a number of studies submitted in support of the application, namely, master data for calcidiol [ANNEX 1_Friederich_Beck, master data calcifediol_PROPRIETARY UNPUBLISHED DATA.pdf]; a comparison of 25(OH)D concentration in human serum/plasma following oral supplementation of calcifediol or cholecalciferol [ANNEX 2_Beck 2016_RD 00053392_ PROPRIETARY UNPUBLISHED DATA.pdf]; the comparative metabolism of [14C]-calcifediol and [14C]-cholecalciferol following multiple oral administration in the intact male han wistar rat [ANNEX 3_Beck et al 2017a_ PROPRIETARY UNPUBLISHED DATA.pdf]; the comparative metabolism of [14c]-calcifediol and [14c]-cholecalciferol following single oral administration in the bile duct cannulated male han wistar rat [ANNEX 4_Beck et al 2017b_ PROPRIETARY UNPUBLISHED DATA.pdf]; calcifediol: acute oral toxicity study in rats [ANNEX 5_Weber & Arcelin_2004b_ PROPRIETARY UNPUBLISHED DATA.pdf]; an in-vitro skin irritation test with DSMO47J 17 using a human skin model [ANNEX 6_Remus_2016a_skin irritation_ PROPRIETARY UNPUBLISHED DATA.pdf]; an evaluation of the eye hazard potential of DSMO47J 17 using the bovine corneal opacity and permeability test [ANNEX 7_Remus_2016b_BCOP_ PROPRIETARY UNPUBLISHED DATA.pdf]; an evaluation of the mutagenic activity of D5M0471 17 in an in vitro mammalian cell gene mutation test with L5178Y mouse lymphoma cells [ANNEX 8_Remus 2016c_MLA_ PROPRIETARY UNPUBLISHED DATA.pdf]; assessment of skin sensitization to DSMO471J7 in the mouse (Local Lymph Node Assay) – pre-screen test [ANNEX 9_Remus_2016d_LLNA_PROPRIETARY UNPUBLISHED DATA.pdf]; a micronucleus test in bone marrow cells of the rat with DSM047117 [ANNEX 10_Remus 2016e_in vivo MNT_PROPRIETARY UNPUBLISHED DATA.pdf]; a Salmonella typhimurium and Escherichia coli reverse mutation assay [ANNEX 11_Woehrle & Sokolowski 2013_PROPRIETARY UNPUBLISHED DATA.pdf]; a chromosome aberration test in human lymphocytes in vitro with calcifediol [ANNEX 12_Weber & Schulz 2005_PROPRIETARY UNPUBLISHED DATA.pdf]; a 90-day oral toxicity study with DSM0471 17 by dietary administration in the rat followed by a 28-day recovery period [ANNEX 13_Thiel et al 2014c_PROPRIETARY UNPUBLISHED DATA.pdf]; a 3-month oral toxicity study with Rovimix® D3-500 by dietary administration followed by a 4-week recovery period in Wistar rats [ANNEX 14_Thiel et al 2007_PROPRIETARY UNPUBLISHED DATA.pdf]; a dose finding study in physically non-frail and (pre-)frail elderly to measure 25(OH) vitamin D levels after supplementation with HY.D calcifediol 25 SD/S and vitamin D3 [ANNEX 15_Wittwer 2015_D-Dose_study_PROPRIETARY UNPUBLISHED DATA.pdf]; response of serum 25-hydroxyvitamin D to different doses of Calcifediol 0,25 SD/S compared to vitamin D3 supplementation: a randomized, controlled, double blind, long term pharmacokinetic study [ANNEX 16_Kunz et al_2016_PROPRIETARY UNPUBLISHED DATA.pdf]; a report on the particle size distribution and its annexes [Report DSM_EFSA_Calcifediol_CONF_DATA PROT_NEW_2_0121 (initial report submitted in December 2020 and further updated and replaced by a new version in January 2021) Report DSM_EFSA_Calcifediol_CONF_DATA PROT_NEW_0321; Report Annex 1_1A_CONF_DATA PROTECTED_NEW_280121; Report Annex 1_1B_CONF_DATA PROTECTED_NEW_280121; Report Annex 1_2A_CONF_DATA PROTECTED_NEW_280121; Report Annex 1_2B_CONF_DATA PROTECTED_NEW_280121; Report Annex 1_2C_CONF_DATA PROTECTED_NEW_280121; Report Annex 2_CONF_DATA PROTECTED_NEW_280121; Report_Annex I_1 2_CONF_DATA PROT_202103; Report_Annex I_3_CONF_DATA PROT_202103; Report_Annex I_4_CONF_DATA PROT_202103.].